Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer

A total of 16 premenopausal women with metastatic breast cancer ( N =13) or locally advanced primary breast cancer ( N =3) were treated with a combination of a gonadotropin-releasing hormone agonist goserelin, and a selective aromatase inhibitor anastrozole. All had previously been treated with gose...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2004-02, Vol.90 (3), p.590-594
Main Authors: Forward, D P, Cheung, K L, Jackson, L, Robertson, J F R
Format: Article
Language:English
Subjects:
Adult
Anastrozole
Antineoplastic Agents, Hormonal - administration & dosage
Antineoplastic Agents, Hormonal - pharmacology
Antineoplastic Agents, Hormonal - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Cancer Research
Clinical
Disease Progression
Disease-Free Survival
Drug Resistance
Epidemiology
Estradiol - blood
Female
Goserelin - administration & dosage
Goserelin - pharmacology
Goserelin - therapeutic use
Gynecology. Andrology. Obstetrics
Humans
Injections, Subcutaneous
Mammary gland diseases
Medical sciences
Middle Aged
Molecular Medicine
Nitriles - administration & dosage
Nitriles - pharmacology
Nitriles - therapeutic use
Oncology
Premenopause
Tamoxifen - administration & dosage
Tamoxifen - pharmacology
Tamoxifen - therapeutic use
Treatment Outcome
Triazoles - administration & dosage
Triazoles - pharmacology
Triazoles - therapeutic use
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A total of 16 premenopausal women with metastatic breast cancer ( N =13) or locally advanced primary breast cancer ( N =3) were treated with a combination of a gonadotropin-releasing hormone agonist goserelin, and a selective aromatase inhibitor anastrozole. All had previously been treated with goserelin and tamoxifen. In all, 12 patients (75%) achieved objective response or durable stable disease at 6 months, with a median duration of remission of 17+ months (range 6–47 months). Four patients still have clinical benefit. Introduction of goserelin and tamoxifen resulted in an 89% reduction in mean oestradiol levels (pretreatment vs 6 months=224 vs 24 pmol l −1 ) ( P
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6601557